Carprieve 50 mg Flavoured Tablets for Dogs

국가: 아일랜드

언어: 영어

출처: HPRA (Health Products Regulatory Authority)

유효 성분:

Carprofen

제공처:

Norbrook Laboratories (Ireland) Limited

ATC 코드:

QM01AE91

INN (국제 이름):

Carprofen

복용량:

50 mg/tablet

약제 형태:

Tablet

처방전 유형:

POM: Prescription Only Medicine as defined in relevant national legislation

치료 영역:

carprofen

승인 상태:

Authorised

승인 날짜:

2011-03-21

제품 특성 요약

Health Products Regulatory Authority
08 February 2019
CRN008W9J
Page 1 of 6
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Carprieve 50 mg Flavoured Tablets for Dogs
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
ACTIVE SUBSTANCE:
Carprofen
50
mg
EXCIPIENTS:
For the full list of excipients see section 6.1
3 PHARMACEUTICAL FORM
Tablet.
Light brown, round, flat, bevel edged tablet.
The tablets can be divided into equal parts.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For analgesia and reduction of chronic inflammation, for example in
degenerative
joint disease in the dog.
The tablets also can be used in the management of post operative pain.
4.3 CONTRAINDICATIONS
Do not exceed the stated dose.
Do not use in cats.
Health Products Regulatory Authority
08 February 2019
CRN008W9J
Page 2 of 6
Do not use in dogs suffering from cardiac, hepatic or renal disease,
where there is a
possibility of gastrointestinal ulceration or bleeding, or where there
is evidence of
blood dyscrasia or hypersensitivity to the product.
Do not use in puppies less than 4 months.
Do not use in cases of hypersensitivity to active substance or to any
of the excipients.
Refer to section 4.7 and 4.8
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
See sections 4.3 and 4.5.
4.5 SPECIAL PRECAUTIONS FOR USE
i.Special precautions for use in animals:
Use in aged dogs may involve additional risk. If such a use cannot be
avoided, such
dogs may require a reduced dosage and careful clinical management.
Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there
is a
potential rise of increased renal toxicity.
NSAIDs can cause inhibition of phagocytosis and hence in the treatment
of
inflammatory conditions associated with bacterial infection,
appropriate concurrent
antimicrobial therapy should be instigated.
The chewable tablets are flavoured. In order to avoid any accidental
ingestion, store
tablets out of reach of the animals.
ii.Special precau